British doctors have created the first treatment against pancreatic cancer that does not produce side effects

Experts say that the substance may be used for treating other types of cancer, not only of the pancreas.

A team of researchers from the University of London has created a product capable of stimulating the immune system and destroy cancer cells, thus improving the life of patients diagnosed with pancreatic cancer. The substance, called ,, SME 101 "is considered a step forward in medicine, deoare treat disease that kills those affected in just a few months after the appearance.

Patients were treated with the new type of medicine they felt much better than those treated using chemotherapy. Doctors are very optimistic about treatment invented, although it was only tested on 110 patients.

,, I am very excited. It is the first time we have a treatment that may be a good candidate for fight against pancreatic cancer, one of the deadliest diseases. Incidence is nearly equivalent mortality it causes. It's great, "says Angus Dalgeish, coordinator of research that has resulted in the production of the drug.

Scientists are especially pleased with the result given by IMM-101, since the product is not toxic to the human body. Moreover, the substance was shown to be effective in the fight against one of the most difficult to treat cancers of the pancreas.

Most individuals analyzed (about 85%) had been diagnosed with cancer metastasis. In the testing stages of new substances, the researchers found that patients who were treated using chemotherapy had an average life of 4.4 months, while patients have been given new treatment lived up to 7 months .

In the study that I conducted, doctors administered with gemcitabine new substance commonly used during chemotherapy. Experts have noted that SME-101 ,, then reactivated "those parts of the immune system affected by cancer, helping them to identify pancreatic tumors, because the substances used during chemotherapy can destroy them.

British experts argue, however, that the substance that created it did not produce significant effects in patients treated because their average life was 6.7 months, compared with the average 5.6 months demonstrated if individuals treated with chemotherapy. However, researchers are optimistic and say that the new type of type of immunotherapy may be used to treat other cancers, there is no longer of the pancreas.